Skip to Content

Publications 2013


Whisenant JG, Ayers GD, Loveless ME, Barnes SL, Colvin DC, Yankeelov TE Assessing reproducibility of diffusion-weighted magnetic resonance imaging studies in a murine model of HER2+ breast cancer. Magn Reson Imaging. 2014 Apr;32(3):245-9. doi: 10.1016/j.mri.2013.10.013. Epub 2013 Dec 14. PubMed PMID:24433723; PubMed Central PMCID: PMC3939718.

Li X, Arlinghaus LR, Ayers GD, Chakravarthy AB, Abramson RG, Abramson VG, Atuegwu N, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Bhave SR, Yankeelov TE. DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings. Magn Reson Med. 2014 Apr;71(4):1592-602. doi: 10.1002/mrm.24782. Epub 2013 May 9. PubMed PMID: 23661583; PubMed Central PMCID: PMC3742614.

Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014 Feb;4(2):232-45. doi: 10.1158/2159-8290.CD-13-0286. Epub 2013 Dec 19. PubMed PMID: 24356096; PubMed Central PMCID: PMC3946308.

Su PF, Chi Y. Marginal regression approach for additive hazards models with clustered current status data. Stat Med. 2014 Jan 15;33(1):46-58. doi: 10.1002/sim.5914. Epub 2013 Aug 2. PubMed PMID: 23913626; PubMed Central PMCID: PMC3918483.

Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res. 2013 Dec 15;19(24):6696-702. doi: 10.1158/1078-0432.CCR-13-1746. PubMed PMID: 24345920; PubMed Central PMCID: PMC3880773.

Li CI, Su PF, Shyr Y. Sample size calculation based on exact test for assessing differential expression analysis in RNA-seq data. BMC Bioinformatics. 2013 Dec 6;14:357. doi: 10.1186/1471-2105-14-357. PubMed PMID: 24314022; PubMed Central PMCID: PMC3924199.

Abramson RG, Li X, Hoyt TL, Su PF, Arlinghaus LR, Wilson KJ, Abramson VG, Chakravarthy AB, Yankeelov TE. Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results. Magn Reson Imaging. 2013 Nov;31(9):1457-64. doi: 10.1016/j.mri.2013.07.002. Epub 2013 Aug 15. PubMed PMID: 23954320; PubMed Central PMCID: PMC3807825.

Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MC. Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. Cancer Res. 2013 Oct 15;73(20):6164-74. doi: 10.1158/0008-5472.CAN-13-0527. PubMed PMID: 24130112; PubMed Central PMCID: PMC3801432.

Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS, Arteaga CL. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res. 2013 Oct 15;73(20):6346-58. doi: 10.1158/0008-5472.CAN-13-1385. Epub 2013 Aug 21. PubMed PMID: 23966295; PubMed Central PMCID: PMC4090144.

Bi X, Sterling JA, Merkel AR, Perrien DS, Nyman JS, Mahadevan-Jansen A. Prostate cancer metastases alter bone mineral and matrix composition independent of effects on bone architecture in mice--a quantitative study using microCT and Raman spectroscopy. Bone. 2013 Oct;56(2):454-60. doi: 10.1016/j.bone.2013.07.006. Epub 2013 Jul 15. PubMed PMID: 23867219; PubMed Central PMCID: PMC3799839.

Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova  O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, Gu J, Huang A, Haubst N, Zehetmeier C, Haberl M, Elis W, Kunz C, Heidt AB, Herlihy K, Murtie J, Schuller A, Arteaga CL, Sellers WR, Ettenberg SA. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35. doi: 10.1158/0008-5472.CAN-13-1198. Epub 2013 Aug 8. PubMed PMID: 23928993; PubMed Central PMCID: PMC3924863.

Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Res. 2013 Oct 1;73(19):6013-23. doi: 10.1158/0008-5472.CAN-13-1191. Epub 2013 Aug 5. PubMed PMID: 23918797; PubMed Central PMCID: PMC3790862.

Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CL. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clin Cancer Res. 2013 Oct 1;19(19):5390-401. doi: 10.1158/1078-0432.CCR-13-1038. Epub 2013 Aug 15. PubMed PMID: 23948973; PubMed Central PMCID: PMC3809918.

Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, Cook RS. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. J Clin Invest. 2013 Oct;123(10):4329-43. doi: 10.1172/JCI66764. Epub 2013 Sep 3. PubMed PMID: 23999432; PubMed Central PMCID: PMC3784526

Weis JA, Miga MI, Arlinghaus LR, Li X, Chakravarthy AB, Abramson V, Farley J, Yankeelov TE. A mechanically coupled reaction-diffusion model for predicting the response of breast tumors to neoadjuvant chemotherapy. Phys Med Biol. 2013 Sep 7;58(17):5851-66. doi: 10.1088/0031-9155/58/17/5851. Epub 2013 Aug 6. PubMed PMID: 23920113; PubMed Central PMCID: PMC3791925.

Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14372-7. doi: 10.1073/pnas.1303204110. Epub 2013 Aug 12. PubMed PMID: 23940356; PubMed Central PMCID: PMC3761610.

Cook RS, Jacobsen KM, Wofford AM, DeRyckere D, Stanford J, Prieto AL, Redente E, Sandahl M, Hunter DM, Strunk KE, Graham DK, Earp HS 3rd. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. J Clin Invest. 2013 Aug;123(8):3231-42. doi: 10.1172/JCI67655. Epub 2013 Jul 8. PubMed PMID: 23867499; PubMed Central PMCID: PMC3726162.

Rexer BN, Arteaga CL. Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Res. 2013 Jul 1;73(13):3817-20. doi: 10.1158/0008-5472.CAN-13-0687. Epub 2013 Jun 21. Review. PubMed PMID: 23794708; PubMed Central PMCID: PMC3702635.

Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Cancer Res. 2013 Jul 1;73(13):4075-85. doi: 10.1158/0008-5472.CAN-12-4579. Epub 2013 Apr 30. PubMed PMID: 23633485; PubMed Central PMCID: PMC3702683.

Dennison JB, Molina JR, Mitra S, González-Angulo AM, Balko JM, Kuba MG, Sanders ME, Pinto JA, Gómez HL, Arteaga CL, Brown RE, Mills GB. Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2013 Jul 1;19(13):3703-13. doi: 10.1158/1078-0432.CCR-13-0623. Epub 2013 May 22. PubMed PMID: 23697991; PubMed Central PMCID: PMC3727144.

Rexer BN, Shyr Y, Arteaga CL. Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy. J Clin Oncol. 2013 Jun 10;31(17):2073-5. doi: 10.1200/JCO.2012.48.5243. Epub 2013 May 6. PubMed PMID: 23650407.

Hansen AG, Freeman TJ, Arnold SA, Starchenko A, Jones-Paris CR, Gilger MA, Washington MK, Fan KH, Shyr Y, Beauchamp RD, Zijlstra A. Elevated ALCAM shedding in colorectal cancer correlates with poor patient outcome. Cancer Res. 2013 May 15;73(10):2955-64. doi: 10.1158/0008-5472.CAN-12-2052. Epub 2013 Mar 28. PubMed PMID: 23539446; PubMed Central PMCID: PMC3660148.

Bryce NS, Reynolds AB, Koleske AJ, Weaver AM. WAVE2 regulates epithelial morphology and cadherin isoform switching through regulation of Twist and Abl. PLoS One. 2013 May 15;8(5):e64533. doi: 10.1371/journal.pone.0064533. Print 2013. PubMed PMID: 23691243; PubMed Central PMCID: PMC3654908.

Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 2013 Mar;123(3):1348-58. doi: 10.1172/JCI65416. Epub 2013 Feb 8. PubMed PMID: 23391723; PubMed Central PMCID: PMC3582135.

Chakrabarty A, Bhola NE, Sutton C, Ghosh R, Kuba MG, Dave B, Chang JC, Arteaga CL. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res. 2013 Feb 1;73(3):1190-200. doi: 10.1158/0008-5472.CAN-12-2440. Epub 2012 Nov 29. PubMed PMID: 23204226; PubMed Central PMCID: PMC3563941.

Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res. 2013 Feb 1;19(3):610-9. doi: 10.1158/1078-0432.CCR-12-2024. Epub 2012 Dec 5. PubMed PMID: 23224399; PubMed Central PMCID: PMC3563762.

Whisenant JG, Peterson TE, Fluckiger JU, Tantawy MN, Ayers GD, Yankeelov TE. Reproducibility of static and dynamic (18)F-FDG, (18)F-FLT, and (18)F-FMISO MicroPET studies in a murine model of HER2+ breast cancer. Mol Imaging Biol. 2013 Feb;15(1):87-96. doi: 10.1007/s11307-012-0564-0. PubMed PMID: 22644988; PubMed Central PMCID: PMC3752931.

Friberg A, Vigil D, Zhao B, Daniels RN, Burke JP, Garcia-Barrantes PM, Camper D, Chauder BA, Lee T, Olejniczak ET, Fesik SW. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J Med Chem. 2013 Jan 10;56(1):15-30. doi: 10.1021/jm301448p. Epub 2012 Dec 17. PubMed PMID: 23244564; PubMed Central PMCID: PMC3646517.

Liu Q, Zhao S, Su PF, Yu S. Gene and isoform expression signatures associated with tumor stage in kidney renal clear cell carcinoma. BMC Syst Biol. 2013;7 Suppl 5:S7. doi: 10.1186/1752-0509-7-S5-S7. Epub 2013 Dec 9. PubMed PMID: 24564989; PubMed Central PMCID: PMC4028983.

Fox EM, Kuba MG, Miller TW, Davies BR, Arteaga CL. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast Cancer Res. 2013;15(4):R55. PubMed PMID: 23844554; PubMed Central PMCID: PMC3979036.

Li CI, Su PF, Guo Y, Shyr Y. Sample size calculation for differential expression analysis of RNA-seq data under Poisson distribution. Int J Comput Biol Drug Des. 2013;6(4):358-75. doi: 10.1504/IJCBDD.2013.056830. Epub 2013 Sep 30 PubMed PMID: 24088268; PubMed Central PMCID: PMC3874726.